metformin has been researched along with T-Cell Lymphoma in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosilio, C | 1 |
| Lounnas, N | 1 |
| Nebout, M | 1 |
| Imbert, V | 1 |
| Hagenbeek, T | 1 |
| Spits, H | 1 |
| Asnafi, V | 1 |
| Pontier-Bres, R | 1 |
| Reverso, J | 1 |
| Michiels, JF | 1 |
| Sahra, IB | 1 |
| Bost, F | 1 |
| Peyron, JF | 1 |
| Haugen, BR | 1 |
| Shi, WY | 1 |
| Xiao, D | 1 |
| Wang, L | 1 |
| Dong, LH | 1 |
| Yan, ZX | 1 |
| Shen, ZX | 1 |
| Chen, SJ | 1 |
| Chen, Y | 1 |
| Zhao, WL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metformin in Combination With R-CHOP for the First Line Treatment of Patients With Diffuse Large B-cell Lymphoma[NCT03200015] | Phase 2 | 15 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and T-Cell Lymphoma
| Article | Year |
|---|---|
Drugs that suppress TSH or cause central hypothyroidism.
Topics: Aged; Bexarotene; Dopamine Agonists; Glucocorticoids; Humans; Hypothyroidism; Lymphoma, T-Cell; Male | 2009 |
2 other studies available for metformin and T-Cell Lymphoma
| Article | Year |
|---|---|
The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells.
Topics: Alleles; Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival | 2013 |
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Autophagy; Cell Cycle; Cell Li | 2012 |